Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 98985Y108 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Rubric Capital Management LP
13G/A
Amendment 2
|
9.5% |
5/15/2026
Event 3/31/2026
|
|
| Rubric Capital Management LP | 9.5% | ||
| David Rosen | 9.5% | ||
|
Perceptive Advisors LLC
13G
|
5.4% |
4/15/2026
Event 4/8/2026
|
|
| Perceptive Advisors LLC | 5.4% | ||
| Joseph Edelman | 5.4% | ||
| Perceptive Life Sciences Master Fund, Ltd. | 5.4% | ||
|
Rubric Capital Management LP
13G/A
Amendment 1
|
7.7% |
2/13/2026
Event 12/31/2025
|
|
| Rubric Capital Management LP | 7.7% | ||
| David Rosen | 7.7% | ||
| Morgan Stanley 13G/A Amendment 3 | 3.4% |
2/12/2026
Event 12/31/2025
|
|
|
EcoR1 Capital, LLC
13D/A
Amendment 7
|
30.7% |
11/19/2025
Event 11/16/2025
|
|
| EcoR1 Capital, LLC | 30.7% | ||
| Oleg Nodelman | 30.7% | ||
| EcoR1 Capital Fund Qualified, L.P. | 28.8% | ||
|
Redmile Group, LLC
13G/A
Amendment 6
|
4.9% |
11/14/2025
Event 9/30/2025
|
|
| Redmile Group, LLC | 4.9% | ||
| Jeremy C. Green | 4.9% | ||
|
Biotechnology Value Fund L P
13G/A
Amendment 2
|
5.2% |
11/14/2025
Event 9/30/2025
|
|
| Biotechnology Value Fund L P | 2.7% | ||
| BVF I GP LLC | 2.7% | ||
| Biotechnology Value Fund II LP | 2.1% | ||
| BVF II GP LLC | 2.1% | ||
| Biotechnology Value Trading Fund OS LP | 0.3% | ||
| BVF Partners OS Ltd. | 0.3% | ||
| BVF GP Holdings LLC | 4.9% | ||
| BVF Partners L P/IL | 5.2% | ||
| BVF Inc/IL | 5.2% | ||
| Lampert Mark N | 5.2% | ||
|
Redmile Group, LLC
13G/A
Amendment 5
|
5.6%
Checked 5% or less
|
8/14/2025
Event 6/30/2025
|
|
| Redmile Group, LLC | 5.6% | ||
| Jeremy C. Green | 5.6% | ||
| Redmile Biopharma Investments III, L.P. | 4.6% | ||
| BlackRock, Inc. 13G/A Amendment 1 | 4.8% |
7/16/2025
Event 6/30/2025
|
|
|
EcoR1 Capital, LLC
13D
|
30.7% |
6/27/2025
Event 6/26/2025
|
|
| EcoR1 Capital, LLC | 30.7% | ||
| Oleg Nodelman | 30.7% | ||
| EcoR1 Capital Fund Qualified, L.P. | 28.8% | ||
|
Morgan Stanley
13G/A
Amendment 2
|
5.8%
Checked 5% or less
|
5/7/2025
Event 3/31/2025
|
|
| Morgan Stanley | 5.8% | ||
| Morgan Stanley Capital Services LLC | 4.6% | ||
|
EcoR1 Capital, LLC
13D/A
Amendment 5
|
25.4% |
4/8/2025
Event 4/4/2025
|
|
| EcoR1 Capital, LLC | 25.4% | ||
| Oleg Nodelman | 25.4% | ||
| EcoR1 Capital Fund Qualified, L.P. | 23.9% | ||
|
EcoR1 Capital, LLC
13D/A
Amendment 4
|
24.2% |
3/17/2025
Event 3/13/2025
|
|
| EcoR1 Capital, LLC | 24.2% | ||
| Oleg Nodelman | 24.2% | ||
| EcoR1 Capital Fund Qualified, L.P. | 22.7% | ||
|
EcoR1 Capital, LLC
13D/A
Amendment 3
|
22.8% |
2/18/2025
Event 2/17/2025
|
|
| EcoR1 Capital, LLC | 22.8% | ||
| Oleg Nodelman | 22.8% | ||
| EcoR1 Capital Fund Qualified, L.P. | 21.4% | ||
|
Redmile Group, LLC
13G/A
Amendment 4
|
7.0% |
2/14/2025
Event 12/31/2024
|
|
| Redmile Group, LLC | 7.0% | ||
| Jeremy C. Green | 7.0% | ||
| Redmile Biopharma Investments III, L.P. | 5.0% | ||
|
EcoR1 Capital, LLC
13D/A
Amendment 2
|
22.4% |
1/13/2025
Event 1/10/2025
|
|
| EcoR1 Capital, LLC | 22.4% | ||
| Oleg Nodelman | 22.4% | ||
| EcoR1 Capital Fund Qualified, L.P. | 21.0% | ||
|
EcoR1 Capital, LLC
13D/A
Amendment 1
|
21.3% |
12/23/2024
Event 12/19/2024
|
|
| EcoR1 Capital, LLC | 21.3% | ||
| Oleg Nodelman | 21.3% | ||
| EcoR1 Capital Fund Qualified, L.P. | 20.1% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 3 | 1.32 k | $35.0 k |
| 2026 Q2 | 209 | 70.6 M | $1.86 B |
| 2026 Q1 | 224 | 70.3 M | $1.76 B |
| 2025 Q4 | 226 | 71.5 M | $1.88 B |
| 2025 Q3 | 193 | 73.7 M | $1.26 B |
| 2025 Q2 | 190 | 75.9 M | $953 M |
| 2025 Q1 | 193 | 70.6 M | $841 M |
| 2024 Q4 | 180 | 66.5 M | $973 M |
| 2024 Q3 | 170 | 66.6 M | $835 M |
| 2024 Q2 | 172 | 72.5 M | $617 M |
| 2024 Q1 | 182 | 78.3 M | $824 M |
| 2023 Q4 | 168 | 70.0 M | $727 M |
| 2023 Q3 | 150 | 62.5 M | $396 M |
| 2023 Q2 | 144 | 63.4 M | $548 M |
| 2023 Q1 | 123 | 56.7 M | $513 M |
| 2022 Q4 | 103 | 55.3 M | $434 M |
| 2022 Q3 | 1 | 78.4 k | $482 k |